Erythropoietin-associated PRCA: Still an unsolved mystery

Journal of Immunotoxicology

Volumn 3, Issue 3, 2006, Pages 123-130

  Schellekens, Huub ^a   Jiskoot, Wim ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

Biopharmaceuticals; Epoetin alpha; Epoetin beta; Immunogenicity; Pure red cell aplasia (PRCA); Recombinant human erythropoietin

Indexed keywords

ERYTHROPOIETIN; HUMAN SERUM ALBUMIN; POLYSORBATE 80; RECOMBINANT ERYTHROPOIETIN; STABILIZING AGENT;

AUTOIMMUNE DISEASE; BIOTECHNOLOGY; BLOOD SAMPLING; BONE MARROW BIOPSY; CONFERENCE PAPER; ERYTHROBLAST; ERYTHROCYTE DISORDER; HUMAN; IMMUNOGENICITY; LEACHING; PRIORITY JOURNAL; PROTEIN AGGREGATION; PURE RED CELL ANEMIA;

EID: 33747595483     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910600845567     Document Type: Conference Paper

References (33)

1. Amgen Inc. 2003. Experience reported among erythropoietic products (single product use only). Available at 〈http://www-ext.amgen.com/ clinicians/prca.html〉. Accessed Dec. 5, 2003.
2. Bennett, C. L., Luminari, S., Nissenson, A. R., Tallman, M. S., Klinge, S. A., McWilliams, N., McKoy, J. M., Kim, B., Lyons, E. A., Trifilio, S. M., Raisch, D. W., Evens, A. M., Kuzel, T. M., Schumock, G. T., Belknap, S. M., Locatelli, F., Rossert, J., and Casadevall, N. 2004. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351:1403-1408.
3. Boven, K., Knight, J., Bader, F., Rossert, J., Eckardt, K. U., and Casadevall, N. 2005a. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: Solving the mystery. Nephrol. Dial. Transplant. 20 (Suppl 3):iii33-iii40.
4. Boven, K., Stryker, S., Knight, J., Thomas, A., van Regenmortel, M., Kemeny, D. M., Power, D., Rossert, J., and Casadevall, N. 2005b. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 67:2346-2353.
5. Braun, A., Kwee, L., Labow, M. A., and Alsenz, J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 14:1472-1478.
6. Casadevall, N., Cournoyer, D., Marsh, J., Messner, H., Pallister, C., Parker-Williams, J., and Rossert, J. 2004. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur. J. Haematol. 73:389-396.
7. Casadevall, N., Dupuy, E., Molho-Sabatier, P., Tobelem, G., Varet, B., and Mayeux, P. 1996. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N. Engl. J. Med. 334:630-633.
8. Casadevall, N., Lacombe, C., and Varet, B. 1993. Erythroblastopenia: Chronic idiopathic or associated with chronic lymphoid leukemia. Value of cultures of erythroblastic progenitors and therapeutic strategy. Presse Med. 22:1079-1086.
9. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J. J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., and Mayeux, P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469-475.
10. Chackerian, B., Lenz, P., Lowy, D. R., and Schiller, J. T. 2002. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. 169:6120-6126.
11. Gershon, S. K., Luksenburg, H., Cote, T. R., and Braun, M. M. 2002. Pure red-cell aplasia and recombinant erythropoietin. N. Engl. J. Med. 346:1584-1586.
12. Gribben, J. G., Devereux, S., Thomas, N. S., Keim, M., Jones, H. M., Goldstone, A. H., and Linch, D. C. 1990. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335:434-437.
13. Heavner, G. A., Villalobos, A. P., Gunturi, S. R., and Brennen, P. 2004. Interaction of polysorbate 80 with erythropoietin. Abstracts of the 18th Annual Symposium of the Protein Society, San Diego, California.
14. Hermeling, S., Schellekens H., Crommelin, D. J., and Jiskoot, W. 2003. Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity? Pharm. Res. 20:1903-1907.
15. Jepson, J. H., and Lowenstein L. 1968. Panhypoplasia of the bone marrow. I. Demonstration of a plasma factor with anti-erythropoietin-like activity. Can. Med. Assoc. J. 99:99-101.
16. Johnson & Johnson Pharmaceutical Research & Development. 2005. Summary of PRCA Case Reports: Update on the Actions by Johnson & Johnson Pharmaceutical Research & Development Regarding Erythropoietin Antibody-Positive Pure Red Cell Aplasia. Johnson & Johnson Pharmaceutical Research & Development.
17. Krantz, S. B., Moore, W. H., and Zaentz, S. D. 1973. Studies on red cell aplasia. V. Presence of erythroblast cytotoxicity in G-globulin fraction of plasma. J. Clin. Invest. 52:324-336.
18. Locatelli, F., Aljama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K. U., Macdougall, I. C., Macleod, A., Horl, W. H., Wiecek, A., and Cameron, S. 2004. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: Where are we now and where do we go from here? Nephrol. Dial. Transplant. 19:288-293.
19. Macdougall, I. C. 2004. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr. Med. Res. Opin. 20:83-86.
20. Naim, J. O., Ippolito, K. M., Lanzafame, R. J., and van Oss, C. J. 1995. Induction of type II collagen arthritis in the DA rat using silicone gels and oils as adjuvant. J. Autoimmun. 8:751-761.
21. Naim, J. O., Lanzafame, R. J., and van Oss, C. J. 1993. The adjuvant effect of silicone-gel on antibody formation in rats. Immunol. Invest. 22:151-161.
22. Ottesen, J. L., Nilsson, P., Jami, J., Weilguny, D., Duhrkop, M., Bucchini, D., Havelund, S., and Fogh, J. M. 1994. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:1178-1185.
23. Peschle, C., Marmont, A. M., Marone, G., Genovese, A., Sasso, G. F., and Condorelli, M. 1975. Pure red cell aplasia: Studies on an IgG serum inhibitor neutralizing erythropoietin. Br. J. Haematol. 30:411-417.
24. Preece, M. 1993. Human pituitary growth hormone and Creutzfeldt-Jakob disease. Horm. Res. 39:95-98.
25. Schellekens, H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1:457-462.
26. Schellekens. H. 2003. Biopharmaceutical immunogenicity: Association between epoetin alfa and pure red cell aplasia. Eur. J. Hospital Pharm. 3:68-69.
27. Sharma, R., Bader, F., Templeman, T., Lisi, P., Ryan, M., and Heavner, G. A. 2004. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX. Eur. J. Hospital Pharm. 5:86-91.
28. Smiell, J. M., Schellekens, H., and Crommelin, D. J. 2003. Equivocal role of micelles in Eprex adverse events. Nat. Biotechnol. 21:1265.
29. Stewart, T. A., Hollingshead, P. G., Pitts, S. L., Chang, R., Martin, L. E., and Oakley, H. 1989. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol. Biol. Med. 6:275-281.
30. Villalobos, A. P., Gunturi, S. R., and Heavner, G. A. 2005. Interaction of polysorbate 80 with erythropoietin: A case study in protein-surfactant interactions. Pharm. Res. 22:1186-1194.
31. Wan, L. S., and Lee, P. F. 1974. CMC of polysorbates. J. Pharm. Sci. 63:136-137.
32. Wegewijs, K. 2003. The supply chain for biopharmaceuticals: A manufacturer's view. Eur. J. Hospital Pharm. 1:86-88.
33. Zaentz, S. D., and Krantz, S. B. 1973. Studies on pure red cell aplasia. VI. Development of two-stage erythroblast cytotoxicity method and role of complement. J. Lab. Clin. Med. 82:31-43.